Literature DB >> 33410259

COVID-19-convalescence phase unmasks a silent myocardial infarction due to coronary plaque rupture.

Carsten Tschöpe1,2,3, Mohammad Sherif1, Markus S Anker3,4,5,6, Dominik Geisel7, Titus Kuehne3,8,9, Sebastian Kelle1,3,10.   

Abstract

Increased risk of cardiovascular complications during and post-COVID-19 infection is more and more recognized-including myocarditis, arrhythmias, and myocardial infarctions (MIs). The mechanisms leading to these complications are direct virus-induced injuries, as well as potential thrombotic and inflammatory-induced mechanisms. To the latter, inflammatory plaque instability and plaque rupture are discussed entities contributing to MI-induced post-COVID-19 complications. Our case report describes the first time, when a temporary impairment of LVEF in the COVID-19-convalescence phase unmasks a silent MI due to coronary plaque rupture by using invasive (OCT) and non-invasive (CMR) modalities. Myocardial infarction might be an important differential diagnosis to consider in deteriorating patients with COVID-19, especially if dyspnoea persists after acute infection.
© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Entities:  

Keywords:  CMR; COVID-19; OCT; SARS-CoV-2; convalescence; heart; magnetic resonance; myocardial infarction; myocarditis; recovery; thrombosis

Mesh:

Year:  2021        PMID: 33410259      PMCID: PMC8006695          DOI: 10.1002/ehf2.13186

Source DB:  PubMed          Journal:  ESC Heart Fail        ISSN: 2055-5822


Introduction

Increased risk of cardiovascular complications during and post‐COVID‐19 infection is more and more recognized—including myocarditis, arrhythmias, and myocardial infarctions (MIs). , , , The mechanisms leading to these complications are direct virus‐induced injuries, as well as potential thrombotic and inflammatory‐induced mechanisms. To the latter, inflammatory plaque instability and plaque rupture are discussed entities contributing to MI‐induced post‐COVID‐19 complications. , We are reporting the case of a 74‐year‐old man, who presented with slight cough after a diagnosed SARS‐CoV‐2 infection 6 weeks ago. Besides known and sufficient treated arterial hypertension (ramipril 5 mg twice a day) and hyperlipoproteinaemia (simvastatin 40 mg once a day) as the only pre‐existing diseases, the patient was completely asymptomatic before COVID‐19. A positive PCR for the COVID‐19 virus and confirmation of a diagnosis of COVID‐19‐induced pneumonia at chest‐CT and MRI (bilateral pleural effusion, distinct peripheral consolidation, and reticulations), the patient was hospitalized without intubation for 11 days. During rehabilitation, there was an unexplained drop of left ventricular ejection fraction (LVEF) to 41%. The patient was transferred to our hospital with suspected post‐COVID‐19 myocarditis and presented without severe clinical symptoms (laboratory results: hs‐troponin slightly elevated with 21 ng/L; CRP normal with 3.5 mg/L and NT‐pro‐BNP normal with 69 ng/L; normal ECG without signs of ischaemia). Moreover, the LVEF (measured using Simpson's biplane method) returned to normal (72%) at presentation at our institution. For further evaluation, coronary angiography and cardiac magnetic resonance (CMR) was recommended for the first time. The coronary angiogram (Figure ) revealed a two‐vessel coronary artery disease with severe (80% diameter) reduction (A demonstrates normal left main stem; B indicates high‐grade stenosis) of the mid‐left anterior descending (LAD) artery and intermediate circumflex artery stenosis (TIMI III). It also presented a ruptured plaque with lipid core and thrombus (C) at optical coherence tomography at LAD, which was not seen at distal LAD (D). The patient was treated by placement of a stent into the LAD. Four weeks later, hs‐troponin found to be in the normal range.
Figure 1

Coronary angiogram including OCT and CMR at COVID‐19‐convalescence phase.

Coronary angiogram including OCT and CMR at COVID‐19‐convalescence phase. CMR demonstrated normal LVEF and slightly hypertrophied myocardium with myocardial oedema at anterior/lateral wall, seen on T2‐weighted sequences at mid and apical short‐axis‐orientation (SAX) (indicated by green arrow in F). After contrast administration, perfusion abnormalities (green arrow at G) and late gadolinium enhancement (LGE) of 75% transmurality were detected in the same region (green arrow in H). In T2‐mapping sequences, T2 was increased up to 59 ms (normal 35–51 ms at 3.0T); native T1‐mapping was elevated up to 1398 ms (normal: 1173–1334 ms at 3.0T); extracellular volume (ECV) map (J), based on a T1‐mapping sequence before and after contrast, revealed significantly increased ECV anterior (indicated by green colour) vs. remote myocardium (blue colour in J). This case report describes the first time when a temporary impairment of LVEF in the COVID‐19‐convalescence phase unmasks a silent MI due to coronary plaque rupture. Myocardial infarction might be an important differential diagnosis to consider in deteriorating patients with COVID‐19, especially if dyspnoea persists after acute infection.

Conflict of interest

C.T., M.S.A., and S.K. have received research support by the DZHK (German Centre for Cardiovascular Research) and by the BMBF (German Ministry of Education and Research) and personal fees from Servier, outside the current work. All other authors have nothing to disclose.

Funding

S.K. received research support from Philips Healthcare. C.T. and S.K. received research support by the DZHK (German Centre for Cardiovascular Research) and by the BMBF (German Ministry of Education and Research).
  6 in total

1.  ST-Elevation Myocardial Infarction in Patients With COVID-19: Clinical and Angiographic Outcomes.

Authors:  Giulio G Stefanini; Matteo Montorfano; Daniela Trabattoni; Daniele Andreini; Giuseppe Ferrante; Marco Ancona; Marco Metra; Salvatore Curello; Diego Maffeo; Gaetano Pero; Michele Cacucci; Emilio Assanelli; Barbara Bellini; Filippo Russo; Alfonso Ielasi; Maurizio Tespili; Gian Battista Danzi; Pietro Vandoni; Mario Bollati; Lucia Barbieri; Jacopo Oreglia; Corrado Lettieri; Alberto Cremonesi; Stefano Carugo; Bernhard Reimers; Gianluigi Condorelli; Alaide Chieffo
Journal:  Circulation       Date:  2020-04-30       Impact factor: 29.690

2.  COVID-19-convalescence phase unmasks a silent myocardial infarction due to coronary plaque rupture.

Authors:  Carsten Tschöpe; Mohammad Sherif; Markus S Anker; Dominik Geisel; Titus Kuehne; Sebastian Kelle
Journal:  ESC Heart Fail       Date:  2021-01-06

3.  SARS-CoV-2-related myocarditis-like syndromes Shakespeare's question: what's in a name?

Authors:  Sophie Van Linthout; Karin Klingel; Carsten Tschöpe
Journal:  Eur J Heart Fail       Date:  2020-06-20       Impact factor: 17.349

Review 4.  Society for Cardiovascular Magnetic Resonance (SCMR) recommended CMR protocols for scanning patients with active or convalescent phase COVID-19 infection.

Authors:  Sebastian Kelle; Chiara Bucciarelli-Ducci; Robert M Judd; Raymond Y Kwong; Orlando Simonetti; Sven Plein; Francesca Raimondi; Jonathan W Weinsaft; Timothy C Wong; James Carr
Journal:  J Cardiovasc Magn Reson       Date:  2020-09-03       Impact factor: 5.364

5.  Coronaviruses and the cardiovascular system: acute and long-term implications.

Authors:  Tian-Yuan Xiong; Simon Redwood; Bernard Prendergast; Mao Chen
Journal:  Eur Heart J       Date:  2020-05-14       Impact factor: 29.983

6.  Clinical Characteristics of Covid-19 in New York City.

Authors:  Parag Goyal; Justin J Choi; Laura C Pinheiro; Edward J Schenck; Ruijun Chen; Assem Jabri; Michael J Satlin; Thomas R Campion; Musarrat Nahid; Joanna B Ringel; Katherine L Hoffman; Mark N Alshak; Han A Li; Graham T Wehmeyer; Mangala Rajan; Evgeniya Reshetnyak; Nathaniel Hupert; Evelyn M Horn; Fernando J Martinez; Roy M Gulick; Monika M Safford
Journal:  N Engl J Med       Date:  2020-04-17       Impact factor: 176.079

  6 in total
  10 in total

1.  Association of Blood Viscosity With Mortality Among Patients Hospitalized With COVID-19.

Authors:  Daein Choi; Ori Waksman; Aleesha Shaik; Phyu Mar; Qinzhong Chen; Daniel J Cho; HyoungSup Kim; Robin L Smith; Sascha N Goonewardena; Robert S Rosenson
Journal:  J Am Coll Cardiol       Date:  2022-07-26       Impact factor: 27.203

2.  Silent Myocardial Infarction and Acute Multiorgan Failure in a COVID-19 Patient: A Case Report.

Authors:  Nischit Baral; Andrea Montalbano; Ashiya Khan; Mehak Qureshi; Pankaj Luitel
Journal:  JNMA J Nepal Med Assoc       Date:  2021-10-15       Impact factor: 0.556

3.  COVID-19-convalescence phase unmasks a silent myocardial infarction due to coronary plaque rupture.

Authors:  Carsten Tschöpe; Mohammad Sherif; Markus S Anker; Dominik Geisel; Titus Kuehne; Sebastian Kelle
Journal:  ESC Heart Fail       Date:  2021-01-06

4.  COVID-19 vs. Classical Myocarditis Associated Myocardial Injury Evaluated by Cardiac Magnetic Resonance and Endomyocardial Biopsy.

Authors:  Radu Tanacli; Patrick Doeblin; Collin Götze; Victoria Zieschang; Alessandro Faragli; Christian Stehning; Grigorios Korosoglou; Jennifer Erley; Jakob Weiss; Alexander Berger; Felix Pröpper; Fridolin Steinbeis; Titus Kühne; Franziska Seidel; Dominik Geisel; Thula Cannon Walter-Rittel; Philipp Stawowy; Martin Witzenrath; Karin Klingel; Sophie Van Linthout; Burkert Pieske; Carsten Tschöpe; Sebastian Kelle
Journal:  Front Cardiovasc Med       Date:  2021-12-24

Review 5.  Advanced Imaging Supports the Mechanistic Role of Autoimmunity and Plaque Rupture in COVID-19 Heart Involvement.

Authors:  Maria Elena Laino; Angela Ammirabile; Francesca Motta; Maria De Santis; Victor Savevski; Marco Francone; Arturo Chiti; Lorenzo Mannelli; Carlo Selmi; Lorenzo Monti
Journal:  Clin Rev Allergy Immunol       Date:  2022-01-28       Impact factor: 8.667

6.  Effects of Non-invasive Brain Stimulation on Multiple System Atrophy: A Systematic Review.

Authors:  Mengjie Zhang; Ting He; Quan Wang
Journal:  Front Neurosci       Date:  2021-12-13       Impact factor: 4.677

Review 7.  Interaction of SARS-CoV-2 with cardiomyocytes: Insight into the underlying molecular mechanisms of cardiac injury and pharmacotherapy.

Authors:  Abdulhamid Abdi; Shahad AlOtaiby; Firas Al Badarin; Ali Khraibi; Hamdan Hamdan; Moni Nader
Journal:  Biomed Pharmacother       Date:  2021-12-09       Impact factor: 7.419

Review 8.  The cross-talk of lung and heart complications in COVID-19: Endothelial cells dysfunction, thrombosis, and treatment.

Authors:  Langjiao Liu; Haijiao Jing; Xiaoming Wu; Mengqi Xiang; Valerie A Novakovic; Shuye Wang; Jialan Shi
Journal:  Front Cardiovasc Med       Date:  2022-08-05

Review 9.  Frontiers of COVID-19-related myocarditis as assessed by cardiovascular magnetic resonance.

Authors:  Yi Luo; Ben-Tian Liu; Wei-Feng Yuan; Can-Xian Zhao
Journal:  World J Clin Cases       Date:  2022-07-16       Impact factor: 1.534

10.  Cardiac sequelae after coronavirus disease 2019 recovery: a systematic review.

Authors:  Mohammad Said Ramadan; Lorenzo Bertolino; Rosa Zampino; Emanuele Durante-Mangoni
Journal:  Clin Microbiol Infect       Date:  2021-06-23       Impact factor: 13.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.